AlphAIAlphAI — Financial news for AI agents
globenewswire.comSEP 302 min read$TOVX

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Theriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.

Original reporting
globenewswire.com
Published Sep 30, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TOVX
Bullish
high confidence
Mentioned
$TOVX
Relevance
9/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$TOVXBullishHigh
01

Why it matters

The Nature Medicine publication provides first peer‑reviewed evidence of efficacy, potentially accelerating FDA discussions and investor interest.

02

Market read

Positive trial data could lift TOVX and related biotech stocks, influencing sector sentiment.

03

What to watch

Small trial size and need for Phase 3 confirmation could limit immediate price impact.

Relevance 9/10Novelty 9/10Timing: today

Background

Theriva Biologics (TOVX) is a clinical‑stage biotech developing VCN-01, an oncolytic adenovirus, for pancreatic cancer and other indications.

Company-level read

Ticker impact

$TOVXBullishHigh confidence
Context

Theriva Biologics announced Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer, published in Nature Medicine.

Expected impact

upward pressure as market prices in improved survival outcomes.

Evidence & confidence

First disclosure of peer‑reviewed trial results with efficacy signals; traders can act on potential catalyst for future approvals.

Market effects

Sector

May boost sentiment for oncolytic virus and pancreatic cancer therapeutic sectors.

Regional

US biotech stocks could see modest gains.

Global

Highlights progress in advanced cancer therapies, relevant to global oncology investors.

Counterpoint

What could challenge this read

Skeptics may question durability of survival benefit and regulatory path.

Key entities

  • company
    Theriva Biologics

    Clinical‑stage biotech developing VCN-01.

  • drug
    VCN-01

    Oncolytic adenovirus targeting pancreatic cancer.

Read at source← All news

Related articles

AUG 11
$TOVXMed

Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr

SEC EDGAR 8-K4 min
AUG 6
$TOVXMed

Theriva Biologics, Inc.: Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patient

Theriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.

finanznachrichten.de4 min
JUL 7
$TOVXMedAI 8/10

Theriva Biologics, Inc.: Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) i

Theriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.

finanznachrichten.de2 min